VSV-LCMV-GP Pseudotype Vectors for Glioma Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods for malignant gliomas face inefficiencies in gene transfer and expression, limiting their therapeutic effectiveness due to poor tumor specificity and safety concerns, particularly with existing oncolytic viruses like HSV and adenoviruses, which often result in transient cytolytic effects and recurrence of tumors.
Innovation Solution
Development of a vesicular stomatitis virus (VSV) pseudotype vector system using the glycoprotein GP of the lymphocyte choriomeningitis virus (LCMV) to enhance tumor specificity and reduce toxicity, combined with complementary replicating VSV vectors and tumor-infiltrating packaging cells to achieve targeted and sustained gene delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing oncolytic viruses like HSV and adenoviruses are used for gene therapy, then gene transfer can be achieved, but tumor specificity is poor and neurotoxicity occurs
Solution Approach 1:
The patent applies local quality by replacing the universal VSV-G envelope protein with LCMV-GP, which specifically targets glial cells. This modification makes the vector's tropism localized to the desired cell type (glioma cells) rather than being broadly active across multiple cell types, thereby improving tumor specificity while reducing off-target neurotoxicity to neurons and other healthy cells
Solution Approach 2:
The patent changes the critical parameter of envelope protein identity from VSV-G to LCMV-GP. This parameter change fundamentally alters the vector's cellular tropism and receptor binding properties, transforming it from a non-specific oncolytic virus into a glioma-selective vector that spares healthy neural tissue
2Productivity
If current gene therapy methods are used, then therapeutic genes can be delivered, but gene transfer efficiency and expression are insufficient
Solution Approach 1:
The patent employs self-service through the use of complementary replicating vectors that encode their own missing viral proteins. The trans-complementation system allows the vectors to autonomously supply functional proteins in transduced cells, enabling efficient gene expression without requiring external supplementation or complex delivery systems
Solution Approach 2:
The patent applies preliminary action by pre-equipping the vector system with all necessary viral proteins and replication machinery packaged within the pseudotyped particles. The LCMV-GP envelope and essential viral components are prepared in advance during vector production, enabling immediate and efficient infection and gene expression upon delivery to target cells
3Adaptability or versatility
If VSV-G pseudotyped vectors are used, then broad tropism is achieved, but glioma-specific targeting is reduced
Solution Approach 1:
The patent applies inversion by reversing the approach: instead of using a broadly tropic VSV-G envelope and attempting to restrict targeting through other means, it directly adopts an envelope protein (LCMV-GP) that is inherently specific to glial cells. This inverts the strategy from 'broad then restrict' to 'specific from the start', achieving glioma-targeting through the fundamental choice of envelope protein
Data Source
AI summary
The invention relates to recombinant VSV viruses and viral vectors which produce a glycoprotein GP of the lymphocyte choriomeningitis virus (LCMV) instead of the G protein of the VSV, to virus producing cells which produce LCMV-GP-pseudotyped VSV virions, and to the use of said vectors and cells in the therapy of solid tumors, especially brain tumors.